CHIO', Adriano
 Distribuzione geografica
Continente #
NA - Nord America 25.494
EU - Europa 23.548
AS - Asia 10.000
SA - Sud America 1.474
OC - Oceania 474
AF - Africa 175
Continente sconosciuto - Info sul continente non disponibili 39
Totale 61.204
Nazione #
US - Stati Uniti d'America 24.118
IT - Italia 6.529
CN - Cina 5.274
IE - Irlanda 2.349
DE - Germania 2.229
FR - Francia 2.014
GB - Regno Unito 1.935
SE - Svezia 1.452
ES - Italia 1.382
KR - Corea 1.205
JP - Giappone 1.038
CA - Canada 959
FI - Finlandia 934
UA - Ucraina 905
BR - Brasile 747
NL - Olanda 639
AT - Austria 626
PL - Polonia 577
VN - Vietnam 513
IN - India 481
AU - Australia 422
TR - Turchia 363
MX - Messico 343
BE - Belgio 334
PT - Portogallo 285
RU - Federazione Russa 212
CO - Colombia 210
CH - Svizzera 209
GR - Grecia 206
TW - Taiwan 196
CL - Cile 195
SG - Singapore 165
HK - Hong Kong 162
AR - Argentina 157
RO - Romania 145
DK - Danimarca 141
IL - Israele 128
HR - Croazia 78
ID - Indonesia 73
PE - Perù 68
UZ - Uzbekistan 68
NO - Norvegia 62
IR - Iran 60
EC - Ecuador 57
CZ - Repubblica Ceca 56
NZ - Nuova Zelanda 52
HU - Ungheria 46
PH - Filippine 39
TH - Thailandia 38
EG - Egitto 37
EU - Europa 35
BG - Bulgaria 34
TN - Tunisia 29
SN - Senegal 27
BY - Bielorussia 26
RS - Serbia 24
SI - Slovenia 24
MY - Malesia 23
PK - Pakistan 23
SA - Arabia Saudita 22
ZA - Sudafrica 20
CR - Costa Rica 19
LB - Libano 19
UY - Uruguay 19
KZ - Kazakistan 18
AE - Emirati Arabi Uniti 16
CY - Cipro 15
SK - Slovacchia (Repubblica Slovacca) 15
LT - Lituania 14
MA - Marocco 14
PA - Panama 14
IQ - Iraq 13
CU - Cuba 12
AL - Albania 11
EE - Estonia 10
BA - Bosnia-Erzegovina 9
MU - Mauritius 9
SC - Seychelles 9
VE - Venezuela 9
LU - Lussemburgo 8
NP - Nepal 8
BD - Bangladesh 7
BO - Bolivia 7
GT - Guatemala 7
MT - Malta 7
IS - Islanda 6
NG - Nigeria 6
PS - Palestinian Territory 6
QA - Qatar 6
DO - Repubblica Dominicana 5
DZ - Algeria 5
FO - Isole Faroe 5
PY - Paraguay 5
KE - Kenya 4
LV - Lettonia 4
ML - Mali 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AM - Armenia 3
LK - Sri Lanka 3
MK - Macedonia 3
Totale 61.157
Città #
Beijing 2.691
Chandler 2.469
Dublin 2.243
Houston 1.559
Fairfield 1.191
Ashburn 1.075
Torino 985
Redwood City 881
Jacksonville 812
Villeurbanne 805
Wilmington 750
Princeton 702
Ann Arbor 665
Woodbridge 665
Medford 625
Vienna 545
Seattle 542
Milan 490
Cambridge 470
Warsaw 455
Nyköping 397
Dearborn 368
Dong Ket 343
Boston 305
Pisa 302
Toronto 281
Rome 273
Turin 269
Fremont 248
Tokyo 244
Shanghai 226
London 209
Chengdu 203
Hangzhou 197
Boardman 186
New York 172
Guangzhou 164
Paris 151
Taipei 151
Nanjing 143
Madrid 142
Barcelona 123
Ottawa 119
San Diego 119
Santiago 118
Utrecht 111
Verona 109
Chicago 97
Sanayi 88
Valencia 86
Changsha 85
Norwalk 84
Brussels 82
Washington 81
Munich 80
Sydney 79
Bogotá 77
Bologna 76
Istanbul 76
Seoul 75
Amsterdam 74
Buenos Aires 74
Hefei 74
Duncan 71
São Paulo 71
Wuhan 68
Singapore 65
Zhengzhou 65
Athens 64
Mountain View 64
Falls Church 63
Padova 63
Detroit 62
Lisbon 59
Berlin 58
Hebei 58
Fuzhou 57
Los Angeles 56
Helsinki 55
Atlanta 54
Lima 54
San Francisco 54
Melbourne 53
Murcia 53
Florence 52
Shenyang 51
Brisbane 50
Kunming 49
Phoenix 49
Hanover 48
Jinan 48
Oxford 48
Silver Spring 48
Delhi 46
Modena 46
Philadelphia 45
Central District 44
Pittsburgh 44
Montreal 43
Nanchang 43
Totale 29.602
Nome #
Amyotrophic lateral sclerosis 6.893
Amyotrophic lateral sclerosis: moving towards a new classification system 2.950
Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model 2.800
Disease-modifying therapies in amyotrophic lateral sclerosis 1.518
Specialist palliative care improves the quality of life in advanced neurodegenerative disorders: NE-PAL, a pilot randomised controlled study 1.364
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial 1.163
State of play in amyotrophic lateral sclerosis genetics 1.140
The changing picture of amyotrophic lateral sclerosis: lessons from European registers 881
Pain in amyotrophic lateral sclerosis 741
Amyotrophic lateral sclerosis and food intake 709
Il Bergamini di Neurologia 616
Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study 570
A20 in Multiple Sclerosis and Parkinson’s Disease: Clue to a Common Dysregulation of Anti-Inflammatory Pathways? 499
Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: Ready for efficacy clinical trials? 498
Network Analysis Identifies Disease-Specific Pathways for Parkinson’s Disease 475
Clinical phenotypes and radiological findings in frontotemporal dementia related to TARDBP mutations 444
null 439
A Multicentric Prospective Incidence Study of Guillain-Barre Syndrome in Italy. the ITANG Study 407
The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. 375
C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson’s disease complicated by psychosis or dementia in a Sardinian population 374
The MITOS system predicts long-term survival in amyotrophic lateral sclerosis 359
Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis 344
MRI signatures of the frontotemporal lobar degeneration continuum 332
Incidence of amyotrophic lateral sclerosis in the province of Novara, Italy, and possible role of environmental pollution 330
NADPH oxidase 2 (NOX2) enzyme activation in patients with chronic inflammatory demyelinating polyneuropathy 314
Percorso diagnostico terapeutico assistenziale dell'epilessia. 290
Acoustic reflex patterns in amyotrophic lateral sclerosis 279
Decreased Levels of Foldase and Chaperone Proteins Are Associated with an Early-Onset Amyotrophic Lateral Sclerosis 277
Influence of frontotemporal dementia in ALS patients and caregivers quality of life and depression 274
July 2017 ENCALS statement on edaravone 268
ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry 223
Coffee and Amyotrophic Lateral Sclerosis: A Possible Preventive Role 222
The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease 221
Validation of the revised classification of cognitive and behavioural impairment in ALS 220
Curable or treatable? The implications of different definitions of illness when treating patients affected by Amyotrophic Lateral Sclerosis 219
Acute, Hemorrhagic, Necrotizing Pancreatitis Associated With Riluzole Treatment in a Patient With Amyotrophic Lateral Sclerosis 203
Amyotrophic Lateral Sclerosis Incidence and Previous Prescriptions of Drugs for the Nervous System 202
Genome-wide Analyses Identify KIF5A as a Novel ALS Gene 199
Projected increase in amyotrophic lateral sclerosis from 2015 to 2040 198
The role of arterial blood gas analysis (ABG) in amyotrophic lateral sclerosis respiratory monitoring 198
G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo 195
ATXN2 polyQ intermediate repeats are a modifier of ALS survival. 184
A genome-wide association study of myasthenia gravis 183
Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels. 180
18 F-FDG-PET correlates of cognitive impairment in ALS 173
Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. 170
CHCH10 mutations in an Italian cohort of familial and sporadic amyotrophic lateral sclerosis patients 170
SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis 167
Amyotrophic lateral sclerosis onset after prolonged treatment with a VEGF receptors inhibitor. 165
Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD 165
Validation of the Italian version of self-administered ALSFRS-R scale 161
Genetic correlation between amyotrophic lateral sclerosis and schizophrenia 159
Alcohol and amyotrophic lateral sclerosis: A possible neuroprotective effect 158
Use of genetic testing in amyotrophic lateral sclerosis by neurologists 151
A longitudinal study on quality of life and depression in ALS patient-caregiver couples 149
Age-related penetrance of the C9orf72 repeat expansion 149
Secular trends of amyotrophic lateral sclerosis: The Piemonte and Valle d’Aosta register 148
A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis 147
NOX2 in the hSOD1G93A Transgenic Swine: a preliminary overview 144
C9ORF72 hexanucleotide repeat exerts toxicity in a stable, inducible motor neuronal cell model, which is rescued by partial depletion of Pten 144
ATNX2 is not a regulatory gene in Italian amyotrophic lateral sclerosis patients with C9ORF72 GGGGCC expansion 142
Diffusion Tensor and Voxel Based Morphometry study in patients with amyotrophic lateral sclerosis 140
Proteostasis and ALS: Protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS) 139
Risk factors in the early diagnosis of ALS: European epidemiological studies. 138
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial 138
Erythropoietin in amyotrophic lateral sclerosis: A multicentre, randomised, double blind, placebo controlled, phase III study 136
ALS mutant FUS proteins are recruited into stress granules in induced pluripotent stem cell-derived motoneurons 134
La continuità assistenziale: miraggio o possibilità? 134
The multistep hypothesis of ALS revisited: The role of genetic mutations 134
Does Recognition of Facial Expression of Primary and Social Emotions in ASL Patients Interfere with Social Competence? 133
No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis 132
Constructional apraxia in frontotemporal dementia associated with the C9orf72 mutation: Broadening the clinical and neuropsychological phenotype. 132
Mutations in the CHCHD10 gene are a common cause of familial amyotrophic lateral sclerosis. 132
Large Proportion of Amyotrophic Lateral Sclerosis Cases in Sardinia Due to a Single Founder Mutation of the TARDBP Gene 131
A novel p.Ser108LeufsTer15 SOD1 mutation leading to the formation of a premature stop codon in an apparently sporadic ALS patient: insights into the underlying pathomechanisms 129
Spatial epidemiology of Amyotrophic Lateral Sclerosis in Piedmont and Aosta Valley, Italy: a population-based cluster analysis 128
What is the role of the placebo effect for pain relief in neurorehabilitation? Clinical implications from the Italian consensus conference on pain in neurorehabilitation 128
Factors predicting survival in ALS: a multicenter Italian study 125
A Strange Loop: Effects of emotional facial expressions impaired recognition in ALS Patients and in their Caregivers. 123
Correlation between Apolipoprotein E genotype and brain metabolism in amyotrophic lateral sclerosis 122
Can eye-tracking system communication improve quality of life and mood in ALS patients with locked-in syndrome 121
A Distinct MR Imaging Phenotype in Amyotrophic Lateral Sclerosis: Correlation between T1 Magnetization Transfer Contrast Hyperintensity along the Corticospinal Tract and Diffusion Tensor Imaging Analysis. 120
The Present and the Future of Neuroimaging in Amyotrophic Lateral Sclerosis 118
Assessing and treating pain in movement disorders, amyotrophic lateral sclerosis, severe acquired brain injury, disorders of consciousness, dementia, oncology and neuroinfectivology. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation 118
Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis 116
Influence of cigarette smoking on ALS outcome: A population-based study 116
Persistent idiopathic hypoglossal nerve palsy: A motor neuron disease-mimic syndrome? 114
Increased risk of ALS for frontline workers 114
Tumor cell proliferation and apoptosis in medulloblastoma 110
Non-self-sufficiency as a primary outcome measure in ALS trials 110
Increased cytoplasmic mislocalization of TAR DNA binding protein 43 (TDP-43) in circulating lymphomonocytes of ALS patients recapitulates the major dysfunction featuring motor neurons in the disease. 109
Amyotrophic lateral sclerosis, physical exercise, trauma and sports: results of a population-based pilot case-control study 107
Expression of NOX2 protein in neutrophils of patients with ALS 107
Multicenter validation of [18F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls 103
Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial) 102
Genetic counselling in ALS: facts, uncertainties and clinical suggestions 102
NADPH Oxidases (NOX) Enzymes Induced Oxidative Stress in CIDP Patients 101
Molecular Chaperones in the Pathogenesis of Amyotrophic Lateral Sclerosis: The Role of HSPB1 101
C9ORF72 and parkinsonism: Weak link, innocent bystander, or central player in neurodegeneration? 100
Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis 99
Totale 38.128
Categoria #
all - tutte 139.104
article - articoli 0
book - libri 0
conference - conferenze 20.128
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 159.232


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.312 0 0 0 0 0 0 0 0 0 577 1.135 600
2019/20209.152 524 541 598 852 736 1.354 890 634 939 916 643 525
2020/20218.978 735 563 618 560 833 629 733 511 1.154 903 651 1.088
2021/20228.950 484 459 570 778 618 633 654 583 559 712 1.325 1.575
2022/202311.689 1.208 775 405 952 1.118 2.397 985 793 1.224 545 712 575
2023/20246.735 865 1.008 585 669 689 714 590 899 224 492 0 0
Totale 63.259